



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: **Yu, et al.**

Application Number: 09/589,288

Group Art Unit: 1646

Filed: June 8, 2000

Examiner: Prasad, S.

Title: **Methods of Treatment Using Antibodies** Atty. Docket No. PF343P3C5
to Neutrokin-alpha (as amended)

Statements Under 37 C.F.R. §§ 1.825(a) and (b)

Commissioner for Patents
Washington, D.C. 20231


Sir:

In accordance with 37 C.F.R. § 1.825(a), the undersigned attorney for Applicants hereby states that sequence information contained in the Substitute Sequence Listing submitted herewith is identical to the sequence information contained in the Sequence Listing of the specification as originally filed and, therefore, the Substitute Sequence listing is completely supported by the specification as originally filed. No new matter has been introduced.

In accordance with 37 C.F.R. § 1.825(b), the undersigned attorney for Applicants hereby states that the information in the paper copy of the Substitute Sequence Listing submitted herewith is identical to the information contained in the computer readable form of the Substitute Sequence Listing submitted herewith.

Respectfully submitted,

Dated: May 3, 2002


Kenley K. Hoover (Reg. No. 40,302)
Agent for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Phone: (301) 610-5771

Enclosures
KKH/MS/vsr